Zomedica Corp. Cash Flow Statement
ZOMDF|4 years of annual SEC 10-K data (FY2022-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$18M
FY2025
Free Cash Flow
-$18M
FY2025
Capital Expenditures
$567,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Zomedica Corp. used $18M in operating cash flow and negative free cash flow of $18M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.23 threshold)
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -70.9% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Income | -$81.9M | -$47.0M | -$34.5M | -$17.0M |
| Operating Cash Flow | -$17.6M | -$23.6M | -$16.0M | -$11.7M |
| Capital Expenditures | $567.0K | $5.2M | $11.3M | $787.0K |
| Free Cash Flow | -$18.2M | -$28.8M | -$27.3M | -$12.5M |
| FCF Margin | -56.9% | -105.7% | -108.5% | -65.8% |